Equities researchers at StockNews.com assumed coverage on shares of Martin Midstream Partners (NASDAQ:MMLP – Get Free Report) in a research note issued on Saturday. The firm set a “buy” rating on the pipeline company’s stock.
Martin Midstream Partners Trading Down 0.5 %
MMLP opened at $3.97 on Friday. The business’s fifty day simple moving average is $3.84 and its 200-day simple moving average is $3.54. The company has a market capitalization of $154.83 million, a price-to-earnings ratio of 39.70 and a beta of 2.10. Martin Midstream Partners has a 12-month low of $2.04 and a 12-month high of $4.13.
Martin Midstream Partners (NASDAQ:MMLP – Get Free Report) last issued its earnings results on Wednesday, October 16th. The pipeline company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.05). Martin Midstream Partners had a negative return on equity of 6.93% and a net margin of 0.59%. The business had revenue of $170.93 million for the quarter, compared to the consensus estimate of $176.43 million. During the same quarter in the previous year, the company earned ($0.03) earnings per share. On average, equities research analysts predict that Martin Midstream Partners will post 0.16 EPS for the current year.
Institutional Investors Weigh In On Martin Midstream Partners
About Martin Midstream Partners
Martin Midstream Partners L.P., together with its subsidiaries, provides terminalling, processing, storage, and packaging services for petroleum products and by-products primarily in the United States. The company operates in four segments: Terminalling and Storage, Transportation, Sulfur Services, and Specialty Products.
See Also
- Five stocks we like better than Martin Midstream Partners
- What Makes a Stock a Good Dividend Stock?
- Warren Buffett, Cathie Wood Own Nu Holdings, Should You?
- What Investors Need to Know About Upcoming IPOs
- MercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
Receive News & Ratings for Martin Midstream Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Martin Midstream Partners and related companies with MarketBeat.com's FREE daily email newsletter.